Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Diaceutics ( (GB:DXRX) ) is now available.
Diaceutics has launched a new service called Pathology Engagement Liaisons (PEL), securing its first contract worth up to $1.8 million with a top twenty global pharma company. This service is designed to enhance engagement with pathologists for pancreatic cancer testing in the US, utilizing the DXRX platform to drive biomarker education and improve patient outcomes. The contract marks a significant step for Diaceutics, expanding their service offerings and increasing potential revenue per brand, while reinforcing their commitment to improving clinical outcomes through precision medicine.
More about Diaceutics
Diaceutics is a technology and solutions provider for the pharma and biotech industries, offering an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by the DXRX platform, The Diagnostics Network.
YTD Price Performance: 24.82%
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $144M
For an in-depth examination of DXRX stock, go to TipRanks’ Stock Analysis page.
